ET
The startup provides clinical research and development services focused on enhancing Amphotericin B to treat systemic and life-threatening fungal infections. Their approach enables the delivery of a broad spectrum of non-toxic antifungal drugs, improving patient safety and treatment efficacy.
Updated 2 months ago
Funding
$111M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AAFunding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup provides clinical research and development services focused on enhancing Amphotericin B to treat systemic and life-threatening fungal infections. Their approach enables the delivery of a broad spectrum of non-toxic antifungal drugs, improving patient safety and treatment efficacy.